Bridgeway Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Bridgeway Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$221K	Buy	158,900 +116,000	+270%	+$202K	﹤0.01%	1015
2025 Q4	$103K	Buy	42,900 +20,000	+87%	+$43.5K	﹤0.01%	1123
2025 Q3	$41.4K	Hold	22,900	–	–	﹤0.01%	1174
2025 Q2	$27.3K	Sell	22,900 -55,000	-71%	-$75.5K	﹤0.01%	1155
2025 Q1	$158K	Buy	77,900 +3,300	+4%	+$17.8K	﹤0.01%	966
2024 Q4	$449K	Sell	74,600 -2,381	-3%	-$17.3K	0.01%	841
2024 Q3	$539K	Buy	76,981 +18,800	+32%	+$148K	0.01%	846
2024 Q2	$337K	Hold	58,181	–	–	0.01%	948
2024 Q1	$416K	Buy	58,181 +26,200	+82%	+$122K	0.01%	969
2023 Q4	$157K	Buy	+31,981	New	+$169K	﹤0.01%	1180

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgeway Capital Management's ACRV Position: Q1 2026 in Review

Bridgeway Capital Management increased its Acrivon Therapeutics (ACRV) stake by 270% in Q1 2026, buying an estimated $202K and bringing the position to 158,900 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #1015.

Bridgeway Capital Management first reported a position in ACRV in Q4 2023 and has held it in 10 quarters since. The position peaked at $539K in Q3 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Bridgeway Capital Management held 158,900 shares of Acrivon Therapeutics worth $221K as of Q1 2026.
Bridgeway Capital Management bought 116,000 Acrivon Therapeutics shares in Q1 2026, an estimated $202K.
Acrivon Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1015 holding.
Bridgeway Capital Management first reported a position in Acrivon Therapeutics in Q4 2023 and has held it in 10 quarters since.
Bridgeway Capital Management's Acrivon Therapeutics position peaked at $539K in Q3 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.